Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 19c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q3 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $112.21 million versus the consensus estimate of $110.29 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Momo (MOMO) Tops Q2 EPS by 8c; offers guidance
• C3.ai (AI) Tops Q1 EPS by 5c; Offers Guidance
• BNP Paribas Exane Starts NHPC Ltd (NHPC:IN) at Underperform